High-Density Lipoprotein Cholesterol Level Is Associated With Fibrous Cap Thickness in Acute Coronary Syndrome

Ozaki, Yuichi; Tanaka, Atsushi; Komukai, Kenichi; Ishibashi, Keiichiro; Tanimoto, Takashi; Kitabata, Hironori; Ino, Yasushi; Kubo, Takashi; Imanishi, Toshio

doi:10.1253/circj.cj-13-0512

Cited by 23 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this analysis, patients who exhibited thin-capped fibroatheroma at their culprit lesions were more likely to have lower HDL-C level, higher level of LDL-C and high sensitivity-CRP. In addition, HDL-C level was significantly associated with fibrous cap thickness 58) . On multivariate analysis, HDL-C level was an independent predictors of thinner fibrous cap thickness and the presence of thin-capped fibroatheroma 58) .…”

Section: Intravascular Imaging Datamentioning

confidence: 92%

“…In addition, HDL-C level was significantly associated with fibrous cap thickness 58) . On multivariate analysis, HDL-C level was an independent predictors of thinner fibrous cap thickness and the presence of thin-capped fibroatheroma 58) . These observations highlight more high-risk plaque phenotypes in CAD patients with low level of HDL-C.…”

Section: Intravascular Imaging Datamentioning

confidence: 92%

“…In OCT imaging elucidated the relationship of HDL-C level with plaque instability in 261 ACS subjects who received PCI 58) . In this analysis, patients who exhibited thin-capped fibroatheroma at their culprit lesions were more likely to have lower HDL-C level, higher level of LDL-C and high sensitivity-CRP.…”

Section: Intravascular Imaging Datamentioning

confidence: 99%

See 2 more Smart Citations

Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering

et al. 2016

View full text Add to dashboard Cite

─ 217 ─ I. IntroductionLowering low-density lipoprotein cholesterol (LDL-C) is a cornerstone in the current therapeutic guideline to prevent atherosclerotic cardiovascular diseases 1, 2) . This is because numerous large-scale randomized controlled trials have consistently demonstrated the beneficial effect of lowering LDL-C level with a statin for the primary and secondary prevention [3][4][5][6][7][8] . Furthermore, serial intravascular imaging studies have also supported its anti-atherosclerotic effects. Intensive lowering LDL-C has been shown to slow plaque progression and induce its regression if very low LDL-C level is achieved [9][10][11] . However, substantial amount of cardiovascular events still occurs even under intensive control of LDL-C level 12, 13) . The residual cardiovascular risks indicate the need to modulate additional therapeutic targets to further reduce atherosclerotic cardiovascular events.The development and propagation of atherosclerosis is derived by the retention of cholesterol-rich lipoproteins within the subendothelial matrix of the arterial wall. While LDL has been considered as the main atherogenic cholesterol-rich particle, other apolipoprotein-B-containing lipoproteins also contribute to intimal cholesterol deposition. Triglyceride-rich lipoprotein is one of atherogenic particles potentially promoting formation and progression of atherosclerotic plaques 14) . In contrast to these lipoproteins, high-density lipoprotein harbours a variety of atheroprotetcive properties which may have the ability in halting ath- anti-atherosclerotic therapies [9][10][11][16][17][18][19][20] . This review summarizes evidences from clinical and intravascular imaging studies to elucidate the contribution of triglyceride and HDL to atherosclerotic cardiovascular disease (ASCVD) and clinical impact of their modulation. II. TriglycerideTriglyceride exists in plasma as lipoprotein, pseudo lipid-protein complex. Apolipoprotein B is a component of triglycer- Residual cardiovascular risks under statin therapy suggest the need to develop additional therapeutic approach to further improve cardiovascular outcomes. Epidemiological and intravascular imaging studies have revealed the relationship of these lipid targets with atherosclerotic cardiovascular disease, indicating triglyceride and high-density lipoprotein cholesterol (HDL-C) as potential targets for achieving better clinical outcomes. However, clinical efficacy of lowering triglyceride and raising HDL-C level has not been established yet. Although findings from clinical trials testing novel agents targeting these lipid markers are disappointing, further search still continues to identify effective therapeutic approach due to their anti-or pro-atherogenic properties. Intravascular imaging modality has contributed to the elucidation of disease mechanism and the evaluation of novel drugs modulating triglyceride and HDL-C. In this review, anti-or pro-atherogenic properties of triglyceride and HDL-C, its association with clinical outcomes and atheroscle...

show abstract

Section: Intravascular Imaging Datamentioning

confidence: 92%

Section: Intravascular Imaging Datamentioning

confidence: 92%

See 1 more Smart Citation

Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Furthermore, another study of 261 consecutive ACS patients reported that the HDL-C level was positively associated with fibrous-cap thickness. They suggested that HDL-C has potential to be a beneficial therapeutic target for plaque stabilization (60).…”

Section: High-density Lipoprotein (Hdl)mentioning

confidence: 99%

Stabilization of high-risk plaques

Takata¹,

Imaizumi²,

Zhang³

et al. 2016

Cardiovasc. Diagn. Ther.

View full text Add to dashboard Cite

“…However, the "native" level of HDL within the arterial wall is recently attracting the attention of investigators, because various local constituents within plaque have been reported to correlate with the serum HDL level. 15 In the article by Uchida et al, they not only introduce a new attractive technology of their own, but also reveal the local distribution of HDL within the arterial wall, which apparently differs according to the stage of plaque progression. These findings contribute to our understanding of the process of atherosclerosis, and is a representative study showing a realistic, clinical feasibility of intravascular molecular imaging.…”

Section: Editorial Intravascular Molecular Imaging For Atherosclerosismentioning

confidence: 99%

Intravascular Molecular Imaging for Atherosclerosis

Hiro

2014

Circ J

View full text Add to dashboard Cite

High-Density Lipoprotein Cholesterol Level Is Associated With Fibrous Cap Thickness in Acute Coronary Syndrome

Cited by 23 publications

References 39 publications

Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering

Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering

Stabilization of high-risk plaques

Intravascular Molecular Imaging for Atherosclerosis

Contact Info

Product

Resources

About